Thubrikar Aortic Valve, Inc.
Our next-gen Transcatheter Aortic Valve Implantation (TAVI) system was designed for durability. It's shown preclinical superiority, and clinical feasibility.
- Stage Prototype Ready
- Industry Medical Devices and Equipment
- Location Norristown, PA, USA
- Currency USD
- Founded October 2010
- Employees 5
- Incorporation Type C-corp
- Website TAVI.us
Dr. Mano Thubrikar designed Optimum TAV after the natural aortic valve for maximum durability. We started an FIH study in Europe in April 2022, and the first 2 patients are doing very well nearly 3 months after implantation with our PRECISION delivery catheter. In 2018, our first patient was implanted in Brazil, and is also doing very well. Preclinical superiority shown (e.g. 24 years in durability test, less pressure gradient in sheep).
Dr. Thubrikar is a world-renowned authority on the aortic valve. He previously worked as Director of BME at South Dakota School of Mines and Technology; as Edwards Distinguished Research Scientist at Edwards Lifesciences Corp.; as Director of BME at The Heineman Medical Research Center; and as Director of Surgical Research in the Department of Surgery at UVA. Dr. Thubrikar authored “Vascular Mechanics and Pathology” and “The Aortic Valve”.
Mr. Wadke leads the strategic operations of the Company with over 20+ years of cross-functional experience. Prior to the Company, he consulted for early-stage pharmaceutical companies. From 2007-2009, he worked for VGX Pharma in Business Development, including its integration of an acquisition and its merger with Inovio BioMedical (NYSEMKT:INO). He previously worked in financial, marketing, and strategy roles at J.P. Morgan and MB Financial.
Mr. Heble is a registered patent attorney with significant experience handling intellectual property matters related to a wide range of life science-based technologies. Mr. Heble began his legal career with an Am Law 100 law firm, and most recently held the position of Senior Patent Counsel for a Fortune 500 consumer products company.
Mr. Parate has over 20 years of entrepreneurial and management experience in the financial industry. He began his career at Susquehanna International Group, and has since co-founded multiple trading firms. He consults part-time for the Company.
Dr. Zhu is President and Founder of CCRF, a leading CRO for medical devices focused on interventional cardiology in China. Wide Line Limited is the main shareholder of CCRF. He has over 20 years of medical device experience. He has also co-founded start-up companies for interventional cardiology devices and serves as a Board Member to multiple medical companies. He holds an MBBS and an MBA.
Douglas S. HamiltonBoard Director, Principal Investor
Co-Founder and CEO of i3 Pharmaceuticals, LLC and Pontis Pharma, LLC. Previously, Co-Founder and President of Synerx Pharma, LLC, a specialty generic pharmaceutical company (acquired by Mylan in 2011.) Over his 35+ years in senior executive positions in Sourcing, New Product Development/Commercialization, Manufacturing, and Business Development at multiple Big Pharma companies. He earned an MBA, and BS in Chemical Engineering.
One of the first U.S. cardiac surgeons to perform TAVR since its initial approval in 2011. Investigator in multiple aortic PARTNER trials, and other device trials for 25 years. Founding Member of Nebraska Heart Hospital, the only U.S. cardiovascular hospital owned and managed by physicians, and led the program to numerous top ratings in Society of Thoracic Surgery quality metrics and patient outcomes. Board certified by ACMA, and RAPS Member.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.